Stock Ratings / Health Care / NMTC / financials

AEMD (44) PLSM (48) FEMY (35) ICU (33) ⌘ Pro Terminal →

NeuroOne Medical Technologies Corporation (NMTC) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.97 +12.96% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.99

NeuroOne Medical Technologies Corporation (NMTC) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $8.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.99 (+2.14%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-4.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NMTC)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (49/100 Composite)

🔍 WHY NMTC SCORES 49/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (29% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$1.12-14.3% Next Q

Q2 (-2Q)

Grade C-$0.96-4.2% Next Q

Q3 (-1Q)

Grade C-$0.92+5.4% Next Q

Current

Grade D$0.97-5.4% Hist 90D α

Trajectory: C (57) → D (49)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NMTC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NMTC currently carries a cautious 49/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.32) and Max Pain ($1.02) forces dealer call-delta covering toward $6.43.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NMTC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NMTC Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 49%NO 51%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How NMTC Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $2.0M

FY24

Rev $3.5M

FY25

Rev $9.1M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$9.1M	56.5%	-46.5%	-$3.6M	-$2.9M	-45%
FY 2024	$3.5M	31.3%	-80%	-$12.3M	-$11.1M	-45%
FY 2023	$2.0M	56.5%	-80%	-$11.9M	-$12.9M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NMTC)

✓Walkthrough of NMTC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NMTC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -79.36%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.97H $1.02L $0.87C $0.97VOL 33.8K

RES: $2.67SUP: $0.72SMA50: $1.32SMA200: $3.20

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NMTC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NMTC Butterfly Map → + Track NMTC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +163.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NMTC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NMTC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NMTC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NMTC)

Health Care Rank #371 of 1016 ⚔️ AEMD vs NMTC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NMTC vs. AEMD, PLSM, FEMY, ICU)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, NeuroOne Medical Technologies Corporation (NMTC) ranks #371 by composite RQD confidence (49/100, grade D) and #905 by equity capitalization ($8.8M). Within this direct 5-issuer industry benchmark cohort, NMTC leads on earnings valuation at N/A trailing P/E, while NMTC leads on capital efficiency and profitability with -35.0% ROIC and 56.5% gross margin. NMTC currently leads its immediate peer cohort in composite quantitative strength at 49/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NMTC ACTIVE NeuroOne Medical Technologies Corporation	D	49/100	—	56.5%	-35.0%	+12.96%	$8.8M	Benchmark Subject
AEMD Aethlon Medical Inc.	D	44/100	—	—	-35.0%	-0.54%	$8.9M	/aemd-vs-nmtc →
PLSM Pulsenmore Ltd.	D	48/100	—	—	—	-8.48%	$10.5M	/plsm-vs-nmtc →
FEMY Femasys Inc.	D-	35/100	—	62.0%	-35.0%	-3.90%	$11.3M	/femy-vs-nmtc →
ICU SeaStar Medical Holding Corporation	E	33/100	—	95.7%	-35.0%	-6.85%	$12.2M	/icu-vs-nmtc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001500198

In its most recent audited fiscal period (FY2025, filed 2025-09-30), NeuroOne Medical Technologies Corporation (NMTC) reported GAAP revenue of $9.1M (+163.5% vs. FY2024 revenue of $3.5M , and +366.0% cumulative change since FY2023) , GAAP net income of -$3.6M, operating cash flow of -$2.8M, and free cash flow of -$2.9M (+73.8% YoY). On the balance sheet, NMTC closed FY2025 with $8.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-09-30	$9.1M	-$3.6M	-$2.8M	-$2.9M	$8.6M	—
FY2024 (FY)	2024-09-30	$3.5M	-$12.3M	-$11.0M	-$11.1M	$6.5M	—
FY2023 (FY)	2023-09-30	$2.0M	-$11.9M	-$12.9M	-$12.9M	—	—

3. NMTC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NMTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $0.97 (+12.96% 1D, market cap $8.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NMTC ranks #371 in composite RQD confidence.

How does NMTC compare to AEMD and PLSM in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), NMTC carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of 56.5%, and ROIC of -35.0%. By comparison, AEMD (Aethlon Medical Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $8.9M) and PLSM (Pulsenmore Ltd.) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $10.5M). Among the 5-stock peer group, NMTC leads on earnings multiple (N/A) while NMTC leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NMTC?

Per NMTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001500198), NeuroOne Medical Technologies Corporation generated $9.1M in revenue (+163.5% YoY), -$3.6M in net income, and -$2.9M in free cash flow against $8.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NMTC trading relative to its 50-day, 200-day, and 52-week technical levels?

NMTC last traded at $0.97 (+12.96% on volume of 66,810 shares), positioning the stock -26.52% below its 50-day simple moving average ($1.32) and -69.69% below its 200-day simple moving average ($3.20). Across its 52-week range of $0.77 to $6.12, NMTC sits at the 3.7% percentile with a 14-day RSI of 40.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.09).

NMTC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is NeuroOne Medical Technologies Corporation (NMTC)?

In FY 2025 (10-K), NMTC converted $9.1M of revenue into a 56.5% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: NMTC RQD Cockpit NMTC 12M Forecast NMTC Earnings & Move NMTC Dividends & DRIP NMTC Insiders & 13F NMTC Whale Options NMTC Profit Sankey NMTC News & Why